# Synthetic biology The engineering of biology — designing DNA, cells and genetic circuits on computers, building them in biofoundries and scaling them into chemicals, materials and ingredients through the Design-Build-Test-Learn cycle. Source: https://en.bioecon.ru/technology/synthetic-biology/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: EU GMO Directive 2001/18/EC & NGT Regulation | OECD: Industrial biotechnology & genomics | Regulator: FDA/TSCA (USA), EFSA/EMA (EU), NMPA (China)] Synthetic biology applies engineering discipline to living cells: it designs DNA, metabolic pathways and genetic circuits on a computer, builds them from synthesised genes in a biofoundry, tests the resulting strains at high throughput, and scales the best ones into chemicals, materials and food ingredients. The field runs on the Design-Build-Test-Learn (DBTL) cycle, where each iteration is automated and data-fed so that strain improvement compounds over time. Its toolkit spans gene synthesis, chassis organisms such as *Escherichia coli* and *Saccharomyces cerevisiae*, genetic logic circuits, and biocontainment systems (auxotrophy and kill switches) that keep engineered microbes inside the reactor. By 2026 the field is commercial at scale: Ginkgo Bioworks runs an industrial cell-programming foundry, Twist Bioscience supplies silicon-based synthetic DNA, Genomatica's bio-BDO delivers 1,4-butanediol with 100% renewable carbon as a drop-in for nylon, and AMSilk's recombinant spider-silk yarns reached consumer garments in 2026. The market is pulled by decarbonisation of heavy chemistry and by alternative-protein demand, but gated by GMO regulation, especially in the EU where synbio organisms fall under the precautionary GMO directive. The key directions of synthetic biology are: 1. **Metabolic engineering of cell factories:** redesigning microbial metabolism to convert sugar, CO2 or methanol into target molecules — drop-in chemicals, alternative proteins and speciality ingredients. 2. **Gene synthesis and biofoundries:** high-throughput DNA synthesis and automated strain-building platforms that industrialise the Build phase of the DBTL cycle. 3. **Genetic circuits and programmable cells:** logic-gene circuits that make cells sense signals and respond — biosensors, smart probiotics and cell therapies. 4. **Biocontainment and xeno-biology:** kill switches, synthetic auxotrophy and recoded genomes that prevent engineered microbes from surviving or exchanging genes outside the reactor. ### Sectoral value chain ``` [Design: AI pathway & gene design] ──> [Build: DNA synthesis & foundry] ──> [Test: screening & fermentation] │ (chassis cells: E. coli / yeast) │ ▼ [Purified product] <─── [Scale-up: demo bioreactor] <─────┘ ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Design** | Computational design of the metabolic pathway and gene sequences, using AI/CAD tools to predict enzyme function and flux. | **In:** Genome data, AI models, target molecule spec.
**Out:** DNA designs, pathway blueprints. | | **DNA synthesis & assembly** | Silicon-based synthesis of genes and their assembly into pathways in an automated biofoundry. | **In:** DNA designs, synthesiser chips.
**Out:** Assembled gene pathways, plasmids. | | **Strain construction** | Introduction of the pathway into a chassis host (*E. coli*, yeast) and library generation of strain variants. | **In:** Pathways, chassis cells.
**Out:** Variant strain libraries. | | **Screening & fermentation** | High-throughput micro-fermentation and analytics screen variants for titre, rate and yield. | **In:** Strain libraries, feedstock.
**Out:** Performance-ranked lead strains. | | **Scale-up** | Transfer of the lead strain to pilot and demo bioreactors (hundreds to thousands of litres) to validate process economics. | **In:** Lead strains, bioreactors, feedstock.
**Out:** Validated production process. | | **Product & downstream** | Industrial fermentation and downstream purification into a commercial chemical, material or ingredient. | **In:** Production strain, feedstock, DSP train.
**Out:** Purified biobased product. | Cross-cutting technologies of the sector: - **Gene synthesis platforms:** silicon-based DNA synthesis (Twist Bioscience) and cloud gene ordering industrialise the supply of synthetic DNA that feeds every build, cutting cost and turnaround. - **Automated biofoundries:** robotic Design-Build-Test-Learn lines (Ginkgo Bioworks) run thousands of strain variants per cycle so improvement compounds with data. - **Genetic firewall biocontainment:** synthetic auxotrophy, recoded genomes and kill switches restrict engineered microbes to the reactor, addressing the environmental-release risk that gates GMO approval. --- ## US The United States leads synthetic biology through its foundry platforms, DNA-synthesis industry and a regulator that distinguishes engineered microbes under TSCA while funding the field as a national bioeconomy priority. ### Ginkgo foundry, Twist DNA synthesis, bioeconomy EO - **Ginkgo Bioworks and the foundry model:** Ginkgo runs an industrial cell-programming platform that partners across food, agriculture and chemicals, automating the Design-Build-Test-Learn cycle for customers who buy strains rather than build them. - **Twist Bioscience and DNA supply:** Twist manufactures synthetic DNA on a silicon platform and in 2026 launched Complex Genes (early access) for challenging repeat-rich sequences, feeding every downstream build. - **Policy and funding:** the 2022 bioeconomy executive order makes synthetic biology a national priority, with DARPA Living Foundries and DOE bioenergy programmes funding strain and pathway engineering. --- ## CN China treats synthetic biology as a strategic industrial base, backing national foundries and listed cell-factory companies to displace petrochemicals and secure ingredient supply. ### Cathay diacids, national foundries, Bioeconomy strategy - **Cathay Industrial Biotech:** Cathay engineers microbes to produce long-chain dibasic acids, a class of biobased monomers for polymers and lubricants, and is a flagship of China's industrial-synbio push. - **National foundries and hubs:** state investment backs genome-synthesis and strain-engineering platforms at Tianjin, Shanghai and Shenzhen, with Yeast 2.0 chromosome synthesis among the visible outputs. - **Regulation:** engineered organisms fall under the 2021 Biosafety Law and MARA/MOST oversight, with gene-edited crops handled on a track separate from classical GMOs. --- ## EU The European Union develops synthetic biology for the Green Transition — decarbonising heavy chemistry and replacing petrochemicals — but under the strictest GMO regime, which pushes many startups toward US relocation. ### AMSilk spider silk, Bio-BDO, precautionary GMO law - **AMSilk and biomaterials:** AMSilk produces 100% protein-based recombinant spider-silk yarns that reached consumer garments in 2026, and supplies lightweight biotech materials for aerospace and premium apparel. - **Biobased chemistry and alt-protein:** chemical majors integrate synbio for bioplastics and drop-in monomers, while precision-fermentation startups program microbes for animal-free dairy and collagen. - **Precautionary regulation:** under EU law synbio organisms are classified as GMOs (Directive 2001/18/EC) and face EFSA risk assessment; the EIC Accelerator funds startups to bridge the "valley of death" to a first demo plant. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Ginkgo Bioworks** | 🇺🇸 USA | *Foundry (cell programming)* | Automated DBTL strain-engineering platform | commercial | | **Twist Bioscience** | 🇺🇸 USA | *Synthetic DNA / Clonal Genes* | Silicon-based DNA synthesis; Complex Genes (2026) | commercial | | **Genomatica** | 🇺🇸 USA | *GENO Bio-BDO* | 1,4-butanediol from plant sugar; 100% renewable carbon | commercial | | **AMSilk** | 🇩🇪 Germany | *Biosteel spider-silk yarns* | 100% protein-based; consumer garments from 2026 | commercial | | **Cathay Industrial Biotech** | 🇨🇳 China | *Long-chain dibasic acids* | Engineered microbes for biobased polymer monomers | commercial | | **Novonesis** | 🇩🇰 Denmark | *Biosolutions* | Biosynthesis, enzymes and biosolutions for industry | commercial | --- ## Tech stack and innovations The synthetic-biology stack joins computational design, automated DNA building and biocontainment into an industrial workflow. 1. **Gene synthesis and biofoundries:** - Silicon-based DNA synthesis (Twist Bioscience) manufactures genes at scale, and Complex Genes extends synthesis to difficult repeat-rich and secondary-structure sequences that long blocked pathway builds. - Foundry platforms (Ginkgo Bioworks) automate the Design-Build-Test-Learn cycle so thousands of strain variants are built and screened per cycle, turning strain engineering into a data-compounding industrial process. 2. **Metabolic engineering of cell factories:** - Pathways are redesigned into chassis hosts — *E. coli* and *S. cerevisiae* — to convert sugar, methanol or CO2 into target molecules; Genomatica's bio-BDO delivers a drop-in 1,4-butanediol with fully renewable carbon for nylon and spandex. - Cathay Industrial Biotech and Novonesis extend cell-factory production to long-chain dibasic acids and biosolutions, displacing petrochemical routes across polymer, lubricant and ingredient markets. 3. **Genetic circuits and biocontainment:** - Logic-gene circuits let cells sense a signal and respond — biosensors, smart probiotics that deliver therapeutics at a tumour, and optogenetic switches that control cell growth with light. - Biocontainment systems — synthetic auxotrophy for non-standard amino acids, recoded genomes and kill switches — restrict engineered microbes to the reactor, the technical answer to the environmental-release risk that gates approval. --- ## Value chains and production pipelines ### DBTL-to-product pipeline for an engineered cell factory (ISO 9001 / GMO-compliant containment) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Design: AI pathway & │ ───> │ 2. Build: DNA synthesis & │ │ gene design │ │ foundry assembly │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Test: high-throughput │ <─── │ 3. Strain construction in │ │ screening │ │ chassis host │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Scale-up in demo │ ───> │ 6. Industrial fermentation│ │ bioreactors │ │ & downstream product │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Design Computational tools design the metabolic pathway and gene sequences for the target molecule, using AI and enzyme databases to predict function, flux and toxicity, and outputting a build-ready DNA design. #### Stage 2: Build The designed genes are synthesised on a silicon platform, assembled into pathways in an automated biofoundry, and prepared as construct libraries ready to transform a chassis host. #### Stage 3: Strain construction The pathway libraries are introduced into a chassis — *E. coli* or yeast — to generate thousands of strain variants, each a candidate cell factory whose performance must be measured. #### Stage 4: Test High-throughput micro-fermentation and mass-spectrometry analytics screen the variant library for titre, rate and yield, ranking strains and feeding the data back into the next design cycle (Learn). #### Stage 5: Scale-up The lead strain is moved to pilot and demonstration bioreactors to validate mixing, gas transfer and process economics, and to lock the downstream purification train before industrial rollout. #### Stage 6: Industrial fermentation and product At commercial scale the production strain ferments feedstock into the target molecule, which is recovered and purified to a biobased chemical, material or ingredient — sold as a drop-in replacement for the petrochemical or animal-derived original.